{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+C&page=14", "query": { "intervention": "Dose C", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 3877, "total_pages": 388, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+C&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+C&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T03:46:00.648Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07000136", "title": "A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heterozygous Familial Hypercholesterolaemia" ], "interventions": [ { "name": "AZD0780", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 473, "start_date": "2025-06-10", "completion_date": "2027-01-04", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-10-20T03:46:00.648Z", "location_count": 19, "location_summary": "Garden Grove, California • San Diego, California • Miami Lakes, Florida + 16 more", "locations": [ { "city": "Garden Grove", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Miami Lakes", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Peachtree Corners", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07000136" }, { "nct_id": "NCT05614544", "title": "Dose-Finding and Human Abuse Potential Study Of HSK3486 Injection In Nondependent, Recreational Central Nervous System Depressant Users", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "General Anesthesia" ], "interventions": [ { "name": "HSK3486", "type": "DRUG" }, { "name": "Propofol", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Haisco-USA Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 42, "start_date": "2022-08-16", "completion_date": "2023-10-03", "has_results": false, "last_update_posted_date": "2023-10-13", "last_synced_at": "2026-10-20T03:46:00.648Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05614544" }, { "nct_id": "NCT06290934", "title": "Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "emvistegrast", "type": "DRUG" }, { "name": "Placebo-to-match emvistegrast", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 228, "start_date": "2024-03-27", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2026-04-09", "last_synced_at": "2026-10-20T03:46:00.648Z", "location_count": 57, "location_summary": "Peoria, Arizona • Camarillo, California • Garden Grove, California + 46 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Camarillo", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Inglewood", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06290934" }, { "nct_id": "NCT02311361", "title": "Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Neoplasms", "Pancreatic Cancer", "Cancer of Pancreas", "Cancer of the Pancreas", "Pancreas Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Tremelimumab", "type": "BIOLOGICAL" }, { "name": "Sterostatic body radiation therapy (SBRT)", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 65, "start_date": "2015-03-25", "completion_date": "2020-12-31", "has_results": true, "last_update_posted_date": "2021-04-20", "last_synced_at": "2026-10-20T03:46:00.648Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02311361" }, { "nct_id": "NCT00117598", "title": "Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Temsirolimus (CCI-779)", "type": "DRUG" }, { "name": "Investigator's choice", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 169, "start_date": "2005-05", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2015-03-30", "last_synced_at": "2026-10-20T03:46:00.648Z", "location_count": 19, "location_summary": "Little Rock, Arkansas • Fountain Valley, California • Los Angeles, California + 16 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Milford", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00117598" }, { "nct_id": "NCT07624513", "title": "D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Isatuximab", "type": "DRUG" }, { "name": "Iberdomide", "type": "DRUG" }, { "name": "Bortezomib (B)", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Linvoseltamab", "type": "DRUG" }, { "name": "On Body Delivery System (OBDS)", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 720, "start_date": "2026-08-31", "completion_date": "2038-03-01", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-20T03:46:00.648Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07624513" }, { "nct_id": "NCT04027023", "title": "Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Diabetes mellitus Type 2 De-escalation treatment (DET)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sciema UG", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2019-10-30", "completion_date": "2021-05-31", "has_results": false, "last_update_posted_date": "2021-04-01", "last_synced_at": "2026-10-20T03:46:00.648Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04027023" }, { "nct_id": "NCT01076842", "title": "Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Type 2" ], "interventions": [ { "name": "Insulin-Levemir", "type": "DRUG" }, { "name": "Exenatide-Bayetta", "type": "DRUG" }, { "name": "Insulin-Levemir and Exenatide-Bayetta", "type": "DRUG" }, { "name": "SenseWear Pro3® armband", "type": "DEVICE" }, { "name": "DexCom CGM", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 75, "start_date": "2008-04", "completion_date": "2011-04", "has_results": false, "last_update_posted_date": "2011-06-27", "last_synced_at": "2026-10-20T03:46:00.648Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01076842" }, { "nct_id": "NCT01430442", "title": "Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Migraine", "Acute Treatment of Migraine" ], "interventions": [ { "name": "Rimegepant", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Sumatriptan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 1026, "start_date": "2011-10", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2023-02-28", "last_synced_at": "2026-10-20T03:46:00.648Z", "location_count": 41, "location_summary": "Scottsdale, Arizona • Tempe, Arizona • San Francisco, California + 35 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Spring Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01430442" }, { "nct_id": "NCT02269917", "title": "Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Human Immunodeficiency Virus Type 1" ], "interventions": [ { "name": "D/C/F/TAF", "type": "DRUG" }, { "name": "Boosted Protease Inhibitor (bPI)", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen R&D Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1149, "start_date": "2015-03", "completion_date": "2020-10", "has_results": true, "last_update_posted_date": "2021-12-09", "last_synced_at": "2026-10-20T03:46:00.648Z", "location_count": 38, "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 35 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02269917" } ] }